Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project)

AIDS Res Hum Retroviruses. 2015 Aug;31(8):837-40. doi: 10.1089/AID.2015.0105. Epub 2015 Jun 2.

Abstract

The Kento-Mwana project was carried out in Pointe Noire, Republic of the Congo, to prevent mother-to-child HIV-1 transmission. To determine the prevalence of different subtypes and transmitted drug resistance-associated mutations, 95 plasma samples were collected at baseline from HIV-1-positive naive pregnant women enrolled in the project during the years 2005-2008. Full protease and partial reverse transcriptase sequencing was performed and 68/95 (71.6%) samples were successfully sequenced. Major mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors were detected in 4/68 (5.9%), 3/68 (4.4%), and 2/68 (2.9%) samples, respectively. Phylogenetic analysis of HIV-1 isolates showed a high prevalence of unique recombinant forms (24/68, 35%), followed by CRF45_cpx (7/68, 10.3%) and subsubtype A3 and subtype G (6/68 each, 8.8%). Although the prevalence of transmitted drug resistance mutations appears to be currently limited, baseline HIV-1 genotyping is highly advisable in conjunction with antiretroviral therapy scale-up in resource-limited settings to optimize treatment and prevent perinatal transmission.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cluster Analysis
  • Congo / epidemiology
  • Drug Resistance, Viral*
  • Female
  • Genotype
  • HIV Infections / epidemiology
  • HIV Infections / virology*
  • HIV Protease / genetics
  • HIV Reverse Transcriptase / genetics
  • HIV-1 / classification*
  • HIV-1 / drug effects*
  • HIV-1 / genetics
  • HIV-1 / isolation & purification
  • Humans
  • Infant, Newborn
  • Molecular Sequence Data
  • Mutation*
  • Phylogeny
  • Pregnancy
  • Pregnancy Complications, Infectious / epidemiology
  • Pregnancy Complications, Infectious / virology*
  • Prevalence
  • Sequence Analysis, DNA
  • Sequence Homology

Substances

  • reverse transcriptase, Human immunodeficiency virus 1
  • HIV Reverse Transcriptase
  • HIV Protease
  • p16 protease, Human immunodeficiency virus 1

Associated data

  • GENBANK/EU914159
  • GENBANK/EU914160
  • GENBANK/EU914161
  • GENBANK/EU914162
  • GENBANK/EU914163
  • GENBANK/EU914164
  • GENBANK/EU914165
  • GENBANK/EU914166
  • GENBANK/EU914167
  • GENBANK/EU914168
  • GENBANK/EU914169
  • GENBANK/EU914170
  • GENBANK/EU914171
  • GENBANK/EU914172
  • GENBANK/EU914173
  • GENBANK/EU914174
  • GENBANK/EU914175
  • GENBANK/EU914176
  • GENBANK/EU914177
  • GENBANK/EU914178
  • GENBANK/EU914179
  • GENBANK/EU914180
  • GENBANK/EU914181
  • GENBANK/EU914182
  • GENBANK/EU914183
  • GENBANK/EU914184
  • GENBANK/EU914185
  • GENBANK/EU914186
  • GENBANK/EU914187
  • GENBANK/KP889062
  • GENBANK/KP889063
  • GENBANK/KP889064
  • GENBANK/KP889065
  • GENBANK/KP889066
  • GENBANK/KP889067
  • GENBANK/KP889068
  • GENBANK/KP889069
  • GENBANK/KP889070
  • GENBANK/KP889071
  • GENBANK/KP889072
  • GENBANK/KP889073
  • GENBANK/KP889074
  • GENBANK/KP889075
  • GENBANK/KP889076
  • GENBANK/KP889077
  • GENBANK/KP889078
  • GENBANK/KP889079
  • GENBANK/KP889080
  • GENBANK/KP889081
  • GENBANK/KP889082
  • GENBANK/KP889083
  • GENBANK/KP889084
  • GENBANK/KP889085
  • GENBANK/KP889086
  • GENBANK/KP889087
  • GENBANK/KP889088
  • GENBANK/KP889089
  • GENBANK/KP889090
  • GENBANK/KP889091
  • GENBANK/KP889092
  • GENBANK/KP889093
  • GENBANK/KP889094
  • GENBANK/KP889095
  • GENBANK/KP889096
  • GENBANK/KP889097
  • GENBANK/KP889098